Combination chemotherapy of carboplatin and gemcitabine against solid tumors: A phase I trial

International Journal of Clinical Oncology

Volumn 6, Issue 6, 2001, Pages 279-283

  Tassinari, D ^a   Drudi, G ^a   Panzini, I ^a   Pasini, G ^a   Arcangeli, V ^a   Fochessati, F ^a   Gianni, L ^a   Mianulli, A M ^a   Oliverio, G ^a   Pasquini, E ^a   Sartori, S ^b   Ravaioli, A ^a  

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Carboplatin; Chemotherapy; Gemcitabine; Phase I trial

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC DISEASES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; TREATMENT OUTCOME;

EID: 18244366116     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-001-8028-6     Document Type: Article

References (37)

1. Interaction between cisplatin and gemcitabine in vitro and in vivo
2. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non small cell lung cancer
3. Phase I dose escalation trial of gemcitabine and cisplatin for advanced non small cell lung cancer: Usefulness of mathematic modeling to determine maximum tolerated dose
4. Phase I/II study of gemcitabine and cisplatin in non small cell lung cancer: Preliminary results
5. Cisplatin gemcitabine combination in advanced non small cell lung cancer: A phase II study
6. Weekly gemcitabine with montly cisplatin: Effective chemotherapy for advanced non small cell lung cancer
7. Extended survival in stage III and IV non small cell lung cancer (NSCLC) patients treated with gemcitabine plus monthly cisplatin
8. Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results
9. Phase II study of regimen of gemcitabine and cisplatin in advanced non small cell lung cancer
10. Monthly gemcitabine (days 1,8, and 15) plus cisplatin (days 1-3) in advanced non small cell lung cancer: A phase II study
11. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small cell lung cancer
12. A 3-week schedule of gemcitabine-cisplatin in advanced non small cell lung cancer with two different cisplatin dose levels: A phase II randomized trial
13. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group
14. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non small cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer
15. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
16. Combined cisplatin and gemcitabine for non small cell lung cancer: Influence of scheduling on toxicity and drug delivery
17. Gemcitabine and carboplatin in combination. An update of phase I and phase II studies in non small cell lung cancer
18. Phase I studies of gemcitabine combined with carboplatin or paclitaxel
19. A phase I study of gemcitabine and carboplatin in non small cell lung cancer
20. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non small cell lung cancer
21. Gemcitabine and carboplatinum in advanced non small cell lung carcinoma: Results of a single institution phase II trial
22. First line therapy with gemcitabine (GEMTRO®) (G) and carboplatin (C) in patients (pts) with advanced non small cell lung cancer (NSCLC): A phase II study
23. Phase II trial of gemcitabine and carboplatin in advanced non small cell lung cancers
24. A phase II study of carboplatin plus gemcitabine in non small cell lung cancer
25. A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non small cell lung carcinoma (NSCLC)
26. Carboplatin (CARBO) in combination with gemcitabine (GEM) in advanced non small cell lung cancer (NSCLC). Comparison of two consecutive phase II trials using different schedules
27. Gemcitabine plus carboplatin in advanced non small cell lung cancer (NSCLC): A phase I trial
28. A phase II study of gemcitabine plus carboplatin in chemonaive patients with advanced non small cell lung cancer (NSCLC)
29. A dose finding study of carboplatin with fixed doses of gemcitabine in "unfit" patients with advanced bladder cancer
30. A phase I study of gemcitabine and carboplatin in advanced non small cell lung carcinoma (NSCLC)
31. Low dose carboplatin (C) and gemcitabine (G) in advanced non small cell lung cancer (NSCLC): An active combination with low toxicity
32. Phase II study of carboplatin (C) and gemcitabine (G) in advanced non small cell lung cancer (NSCLC)
33. Gemcitabine (G) and carboplatin (C) in patients (Pts) with relapsed ovarian cancer (ROC): A phase I-II study
34. Randomized phase III study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer
35. A new schedule of gemcitabine cisplatin in advanced non small cell lung cancer (NSCLC) with two different cisplatin dose levels: A phase II randomized trial
36. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project